ArticleEULAR rheumatology open2025

Which are the clinical characteristics that lead to the decision of primary or secondary usage of TNFi or IL-17i in patients with axial spondyloarthritis?: Real-world evidence from the RABBIT-SpA cohort.

Anne C Regierer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.